Investigational New Drugs

, Volume 32, Issue 4, pp 769–773 | Cite as

Kidney injuries related to ipilimumab

  • Hassane IzzedineEmail author
  • Victor Gueutin
  • Chems Gharbi
  • Christine Mateus
  • Caroline Robert
  • Emilie Routier
  • Marina Thomas
  • Alain Baumelou
  • Philippe Rouvier


Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called “immune-related adverse events” (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.


Melanoma Acute kidney injury Granulomatous interstitial nephritis CTLA-4 inhibitors 


Conflict of interest

The authors declare no financial conflict of interest.


  1. 1.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci 100:4712–4717PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA (2009) CD4+ Regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421–434PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237–e240CrossRefPubMedGoogle Scholar
  5. 5.
    Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8:e537–545CrossRefGoogle Scholar
  6. 6.
    Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283–2289PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211–212CrossRefPubMedGoogle Scholar
  8. 8.
    Forde PM, Rock K, Wilson G, O’Byrne KJ (2012) Ipilimumab-induced immune-related renal failure—a case report. Anticancer Res 32:4607–4608PubMedGoogle Scholar
  9. 9.
    Lebbe C, O’Day S, Chiarion Sileni V, Gajewski T, Pehamberger H, Bondarenko I, Queirolo P, Lundgren S, Roman L, Verschraegen C, Ibrahim R, Chin K, Hoos A, Maio M (2008). Analysis of the onset and resolution of immune related adverse events during treatment with ipilimumab in patients with metastatic melanoma. (oral abstract O-015, Perspectives in Melanoma XII).Google Scholar
  10. 10.
    Haas M, Spargo BH, Wit EJ, Meehan SM (2000) Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 35:433–447CrossRefPubMedGoogle Scholar
  11. 11.
    Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ (2006) Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17:2919–2927CrossRefPubMedGoogle Scholar
  12. 12.
    Clarkson MR, Giblin L, O’Connell FP, O’Kelly P, Walshe JJ, Conlon P, O’Meara Y, Dormon A, Campbell E, Donohoe J (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19:2778–2783CrossRefPubMedGoogle Scholar
  13. 13.
    Bhaumik SK, Kher V, Arora P, Rai PK, Singhal M, Gupta A, Pandey R, Sharma RK (1996) Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 18:97–104CrossRefPubMedGoogle Scholar
  14. 14.
    Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A (2000) The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 54:179–190PubMedGoogle Scholar
  15. 15.
    Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M (2011) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28:1140–1144CrossRefPubMedGoogle Scholar
  16. 16.
    Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y (2005) Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106:3127–3133PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68–73CrossRefPubMedGoogle Scholar
  18. 18.
    Bennett CL, Ochs HD (2001) IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 13:533–538CrossRefPubMedGoogle Scholar
  19. 19.
    Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21CrossRefPubMedGoogle Scholar
  20. 20.
    Liu SM, Sutherland AP, Zhang Z, Rainbow DB, Quintana FJ, Paterson AM, Sharpe AH, Oukka M, Wicker LS, Kuchroo VK (2012) Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J Immunol 188:155–162PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166:6430–6436CrossRefPubMedGoogle Scholar
  22. 22.
    Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T (1999) Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 162:4328–4335PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Hassane Izzedine
    • 1
    Email author
  • Victor Gueutin
    • 1
  • Chems Gharbi
    • 1
  • Christine Mateus
    • 3
  • Caroline Robert
    • 3
  • Emilie Routier
    • 3
  • Marina Thomas
    • 3
  • Alain Baumelou
    • 1
  • Philippe Rouvier
    • 2
  1. 1.Department of NephrologyPitie-SalpetriereParisFrance
  2. 2.Department of PathologyPitie Salpetriere HospitalParisFrance
  3. 3.Department of Dermatology and INSERM Unit U 981Gustave Roussy InstituteVillejuifFrance

Personalised recommendations